BEN HO PARK
Medical Practice in Baltimore, MD

License number

Pennsylvania MD062051L

Personal information

See more information about BEN HO PARK at radaris.com

Name

Address

Phone

Ben Park

117 Oakbourne Rd, West Chester, PA 19382

(814) 449-0754

Ben Park, age 57

5139 Scenic Dr, Perry Hall, MD 21128

(410) 256-4394

Ben Park

500 College Ave, Swarthmore, PA 19081

(610) 574-5050

Ben Park, age 67

2255 Route 949, Corsica, PA 15829

(814) 379-3859

Ben Park

8810 Walther Ave, Parkville, MD 21234

(410) 663-1373

Professional information

See more information about BEN HO PARK at trustoria.com

Ben Park, Baltimore MD

Work:

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N Broadway St, Baltimore, MD 21287 Jhu
600 N Wolfe St, Baltimore, MD 21287

Dr. Ben H Park, Baltimore MD - MD (Doctor of Medicine)

Specialties:

Oncology, Medical Oncology

Address:

Johns Hopkins University Onclgy
1650 Orleans St SUITE 151, Baltimore 21287
(410) 502-7399 (Phone)

Certifications:

Internal Medicine, 1998, Medical Oncology, 2002

Awards:

Healthgrades Honor Roll

Languages:

English

Hospitals:

Johns Hopkins University Onclgy
1650 Orleans St SUITE 151, Baltimore 21287
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287

Education:

Medical School
Perelman School of Medicine University of Pennsylvania
Graduated: 1996
University Of Pa Health System

Compounds, Compositions And Methods For Treating Hormone-Dependent Maladies

US Patent:

2010004, Feb 25, 2010

Filed:

Apr 6, 2007

Appl. No.:

12/296277

Inventors:

Kurtis E. Bachman - Chester Spring PA, US
Ben Ho Park - Baltimore MD, US

International Classification:

A61K 31/58, A61P 35/00, A61P 15/00, A61P 15/18

US Classification:

514174

Abstract:

A composition and method of using are provided, which composition includes: at least one compound selected from the group including a compound having formula (I), a salt thereof, a prodrug thereof, a compound having formula (II), a salt thereof, a prodrug thereof, and a combination thereof, the compounds being described herein, and a combination thereof, and at least one pharmaceutically acceptable carrier; wherein the composition is suitable for administration to a mammal. Methods of using the compound are also provided.